Positron emission tomography in the management of lymphomas

被引:22
作者
O'Doherty, MJ
Macdonald, EA
Barrington, SF
Mikhaeel, NG
Schey, S
机构
[1] St Thomas Hosp, Guys & St Thomas NHS Trust, Clin PET Ctr, London SE1 7EH, England
[2] St Thomas Hosp, Guys & St Thomas NHS Trust, Dept Radiotherapy, London SE1 7EH, England
[3] St Thomas Hosp, Guys & St Thomas NHS Trust, Dept Haematol, London SE1 7EH, England
关键词
D O I
10.1053/clon.2002.0118
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Positron emission tomography is a functional imaging modality that capitalizes on biochemical changes within tumour cells to localize these changes within the body. As a functional imaging tool, unlike an anatomical imaging tool such as CT, it does not require enlargement of lymph nodes affected by disease but does require sufficient numbers of tumour cells to be present with altered biochemical function to visualize these disease sites. These changes are most commonly monitored using a glucose mimic fluorodeoxyglucose which is not only taken up into tumour cells but is trapped within these cells owing to alterations of the hexokinase and dephosphorylase enzymes. This review examines the current role of FDG PET imaging in patients with Hodgkins and Non-Hodgkins lymphoma and also speculates on future roles for this imaging modality.
引用
收藏
页码:415 / 426
页数:12
相关论文
共 72 条
[1]   Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma [J].
Acland, KM ;
Healy, C ;
Calonje, E ;
O'Doherty, M ;
Nunan, T ;
Page, C ;
Higgins, E ;
Russell-Jones, R .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2674-2678
[2]  
Bakheet SM, 1998, SEMIN NUCL MED, V28, P352
[3]   Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDC-PET) for accurate staging of Hodgkin's disease [J].
Bangerter, M ;
Moog, F ;
Buchmann, I ;
Kotzerke, J ;
Griesshammer, M ;
Hafner, M ;
Elsner, K ;
Frickhofen, N ;
Reske, SN ;
Bergmann, L .
ANNALS OF ONCOLOGY, 1998, 9 (10) :1117-1122
[4]  
Bangerter M, 1999, ACTA ONCOL, V38, P799
[5]  
Bangerter M, 1997, INT J HEMATOL, V66, P517
[6]   Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation [J].
Becherer, A ;
Mitterbauer, M ;
Jaeger, U ;
Kalhs, P ;
Greinix, HT ;
Karanikas, G ;
Pötzi, C ;
Raderer, M ;
Dudczak, R ;
Kletter, K .
LEUKEMIA, 2002, 16 (02) :260-267
[7]  
Brink I, 2001, J NUCL MED, V42, P591
[8]  
Buchmann I, 2001, CANCER, V91, P889
[9]   CT and PET lung image registration and fusion in radiotherapy treatment planning using the chamfer-matching [J].
Cai, JL ;
Chu, JCH ;
Recine, D ;
Sharma, M ;
Nguyen, C ;
Rodebaugh, R ;
Saxena, VA ;
Ali, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (04) :883-891
[10]   Detection of lymphoma in bone marrow by whole-body positron emission tomography [J].
Carr, R ;
Barrington, SF ;
Madan, B ;
O'Doherty, MJ ;
Saunders, CAB ;
van der Walt, J ;
Timothy, AR .
BLOOD, 1998, 91 (09) :3340-3346